Nantahala Capital Management - Q4 2018 holdings

$3.25 Billion is the total value of Nantahala Capital Management's 124 reported holdings in Q4 2018. The portfolio turnover from Q3 2018 to Q4 2018 was 34.0% .

 Value Shares↓ Weighting
IWM BuyISHARES TRput$619,916,000
-16.4%
4,629,700
+5.2%
19.07%
-4.4%
IWM NewISHARES TRcall$207,893,0001,552,600
+100.0%
6.40%
FCAU BuyFIAT CHRYSLER AUTOMOBILES Ncall$129,706,000
-7.1%
8,970,000
+12.5%
3.99%
+6.3%
SGMS BuySCIENTIFIC GAMES CORPcall$124,593,000
-24.3%
6,968,300
+7.6%
3.83%
-13.4%
RH BuyRHcall$81,250,000
+4.0%
678,100
+13.8%
2.50%
+19.0%
WRLD BuyWORLD ACCEP CORP DEL$75,871,000
-8.8%
741,945
+2.0%
2.33%
+4.3%
QURE BuyUNIQURE NV$71,435,000
+4.3%
2,478,667
+31.7%
2.20%
+19.3%
SPY NewSPDR S&P 500 ETF TRput$62,480,000250,000
+100.0%
1.92%
VAC NewMARRIOTT VACATIONS WRLDWDE C$55,992,000794,096
+100.0%
1.72%
THC BuyTENET HEALTHCARE CORPcall$50,992,000
+40.5%
2,975,000
+133.3%
1.57%
+60.8%
CVNA NewCARVANA COcall$47,430,0001,450,000
+100.0%
1.46%
PRTY BuyPARTY CITY HOLDCO INC$43,710,000
+36.2%
4,379,789
+84.9%
1.34%
+55.7%
THC BuyTENET HEALTHCARE CORP$42,389,000
-29.4%
2,473,112
+17.3%
1.30%
-19.3%
GDEN BuyGOLDEN ENTMT INC$40,494,000
-29.9%
2,527,713
+5.0%
1.25%
-19.9%
QADA BuyQAD INCcl a$39,672,000
-15.9%
1,008,709
+21.1%
1.22%
-3.9%
CASH BuyMETA FINL GROUP INC$34,596,000
-22.4%
1,784,227
+230.7%
1.06%
-11.3%
XELA BuyEXELA TECHNOLOGIES INC$32,683,000
-31.2%
8,401,832
+26.1%
1.01%
-21.3%
DXPE BuyDXP ENTERPRISES INC NEW$31,959,000
-17.5%
1,147,964
+18.7%
0.98%
-5.8%
CVNA BuyCARVANA COcl a$28,775,000
-33.8%
879,714
+19.6%
0.88%
-24.4%
CURO BuyCURO GROUP HLDGS CORP$28,116,000
-37.0%
2,962,738
+100.6%
0.86%
-28.0%
AKBA BuyAKEBIA THERAPEUTICS INC$28,004,000
-32.9%
5,064,089
+7.2%
0.86%
-23.2%
IMXI BuyINTERNATIONAL MNY EXPRESS IN$25,996,000
+21.5%
2,173,556
+22.1%
0.80%
+38.9%
AFI BuyARMSTRONG FLOORING INC$24,270,000
-24.5%
2,049,813
+15.4%
0.75%
-13.6%
ONDK BuyON DECK CAP INC$24,048,000
-16.4%
4,075,942
+7.3%
0.74%
-4.4%
GTTN BuyGTT COMMUNICATIONS INC$20,977,000
+128.4%
886,581
+318.9%
0.64%
+161.1%
CZR BuyCAESARS ENTMT CORPcall$20,370,000
-20.5%
3,000,000
+20.0%
0.63%
-9.0%
SGMS BuySCIENTIFIC GAMES CORP$20,065,000
+177.1%
1,122,185
+293.6%
0.62%
+216.4%
CRHM BuyCRH MEDICAL CORP$20,028,000
-18.3%
6,534,155
+6.1%
0.62%
-6.7%
TBBK BuyBANCORP INC DEL$19,644,000
-15.7%
2,467,817
+1.6%
0.60%
-3.7%
ACER BuyACER THERAPEUTICS INC$18,178,000
-14.7%
903,455
+30.7%
0.56%
-2.6%
BPI BuyBRIDGEPOINT ED INC$16,466,000
-16.1%
2,348,865
+21.6%
0.51%
-4.0%
RH BuyRH$14,758,000
+45.7%
123,169
+59.3%
0.45%
+66.3%
ESTA BuyESTABLISHMENT LABS HLDGS INC$13,599,000
+182.1%
495,958
+148.0%
0.42%
+221.5%
PAR BuyPAR TECHNOLOGY CORP$12,110,000
+393.3%
556,799
+403.9%
0.37%
+465.2%
OZK NewBANK OZK$11,415,000500,000
+100.0%
0.35%
BDSI BuyBIODELIVERY SCIENCES INTL IN$10,114,000
+116.7%
2,733,567
+64.0%
0.31%
+146.8%
JYNT BuyJOINT CORP$9,391,000
+7.2%
1,128,693
+10.1%
0.29%
+22.5%
GME NewGAMESTOP CORP NEWcl a$9,232,000731,500
+100.0%
0.28%
SCVL NewSHOE CARNIVAL INCput$9,044,000269,900
+100.0%
0.28%
RMBL BuyRUMBLEON INCcl b$8,793,000
+222.3%
1,634,350
+527.8%
0.27%
+271.2%
FTACU NewFINTECH ACQUISITION CORP IIIunit 12/01/2023$8,427,000842,730
+100.0%
0.26%
LINC BuyLINCOLN EDL SVCS CORP$7,798,000
+42.8%
2,436,805
+0.8%
0.24%
+63.3%
TLYS BuyTILLYS INCcl a$7,733,000
-20.3%
712,103
+39.1%
0.24%
-8.8%
NEOS NewNEOS THERAPEUTICS INC$7,400,0004,485,000
+100.0%
0.23%
DHX BuyDHI GROUP INC$7,310,000
-24.1%
4,809,253
+4.8%
0.22%
-13.1%
IGT NewINTERNATIONAL GAME TECHNOLOGcall$7,315,000500,000
+100.0%
0.22%
SSKN BuySTRATA SKIN SCIENCES INC$7,197,000
-20.5%
2,768,001
+8.2%
0.22%
-9.4%
ELVT BuyELEVATE CREDIT INC$7,089,000
+98.3%
1,582,364
+256.8%
0.22%
+127.1%
VIVE BuyVIVEVE MED INC$6,911,000
-34.7%
6,581,465
+66.7%
0.21%
-25.3%
CBIO NewCATALYST BIOSCIENCES INC$6,748,000855,243
+100.0%
0.21%
APEN BuyAPOLLO ENDOSURGERY INC$6,074,000
-28.9%
1,760,562
+47.7%
0.19%
-18.7%
KIRK BuyKIRKLANDS INCput$4,765,000
+57.4%
500,000
+66.7%
0.15%
+81.5%
NATR BuyNATURES SUNSHINE PRODUCTS IN$4,756,000
-5.8%
583,510
+1.2%
0.15%
+7.4%
ARYA NewARYA SCIENCES ACQUISITION CO$4,683,000452,944
+100.0%
0.14%
CEMI NewCHEMBIO DIAGNOSTICS INC$4,641,000820,000
+100.0%
0.14%
GAIA BuyGAIA INC NEWcl a$4,597,000
-28.6%
443,698
+6.1%
0.14%
-18.5%
RFL BuyRAFAEL HLDGS INC$4,500,000
+21.5%
567,511
+28.7%
0.14%
+38.0%
MFCB BuyMFC BANCORP LTD$4,402,000
-4.4%
846,555
+12.2%
0.14%
+8.9%
CUE BuyCUE BIOPHARMA INC$4,127,000
-46.5%
878,098
+2.9%
0.13%
-38.9%
PIRS BuyPIERIS PHARMACEUTICALS INC$3,613,000
+1.5%
1,358,100
+113.6%
0.11%
+15.6%
DRIO NewDARIOHEALTH CORP$2,698,0003,350,981
+100.0%
0.08%
MOTS NewMOTUS GI HLDGS INC$1,555,000500,000
+100.0%
0.05%
CHACU NewCHARDAN HEALTHCARE ACQUISITIunit 12/13/2023$1,007,000100,000
+100.0%
0.03%
Original filings

The following EDGAR filing(s) were analyzed to create this report:

  • View 13F-HR filed 2019-02-14
Signatures

The EDGAR filing(s) were signed by:

About Nantahala Capital Management

Nantahala Capital Management is a hedge fund that was founded in 2004 by Wil Harkey. The firm is headquartered in Connecticut and has additional offices in New York and North Carolina. Nantahala Capital Management primarily invests in the technology, healthcare, and consumer sectors. The firm has a long-term investment approach and seeks to identify undervalued companies with strong growth potential.

Wil Harkey serves as the CEO and Chief Investment Officer of Nantahala Capital Management. He has over 20 years of experience in the finance industry and previously worked at Goldman Sachs and Maverick Capital. In addition to Harkey, the firm's leadership team includes COO and General Counsel, David Kozak, and CFO, Michael Kozak.

Nantahala Capital Management has a strong track record of generating positive returns for its investors. The firm's flagship fund, the Nantahala Fund, has delivered an annualized return of over 20% since its inception in 2006. The firm's success can be attributed to its disciplined investment approach and focus on long-term value creation.

Overall, Nantahala Capital Management is a well-respected hedge fund with a talented leadership team and a strong track record of performance. However, as with any investment, it is important for investors to conduct their own due diligence and carefully consider the risks before investing in the firm's funds.

It's important to note that this information is for educational purposes only and has not been fact-checked. As with any investment, it's important to do your own research and consult with a financial advisor before making any investment decisions.

Top long-term holdings
NameQuarters ownedLatest quarter ownedMax weighting
ISHARES TR42Q3 202327.2%
CODEXIS INC42Q3 20233.9%
PATHWARD FINANCIAL INC35Q3 20236.3%
SCIENTIFIC GAMES CORP34Q3 20225.3%
DOVER MOTORSPORTS INC34Q3 20210.5%
GOLDEN ENTMT INC33Q3 20232.1%
QAD INC32Q3 20212.6%
SCIENTIFIC GAMES CORP31Q4 20217.7%
DOLBY LABORATORIES INC31Q4 20205.6%
LINCOLN EDL SVCS CORP31Q4 20210.7%

View Nantahala Capital Management's complete holdings history.

Latest significant ownerships (13-D/G)
Nantahala Capital Management Q4 2018 significant holdings filed using form 13D/G when ownership exceeds 5% of a company's total stock issue.
FiledShares Percentage
AYTU BIOPHARMA, INCJune 16, 20231,086,81219.7%
Acer Therapeutics Inc.February 14, 20231,226,1917.5%
Aeglea BioTherapeutics, Inc.February 14, 20234,611,3027.5%
AKUMIN INC.February 14, 20232,206,9602.5%
ALTA EQUIPMENT GROUP INC.February 14, 20231,188,9853.7%
Apollo Endosurgery, Inc.February 14, 20234,056,6279.9%
Autolus Therapeutics plcFebruary 14, 20237,782,0184.7%
Bioventus Inc.February 14, 20233,168,5745.1%
CATALYST BIOSCIENCES, INC.February 14, 2023438,0551.4%
Drive Shack Inc.February 14, 20236,500,0007.0%

View Nantahala Capital Management's complete significant-ownership history.

Latest filings
TypeFiled
42024-03-21
42024-03-15
SC 13G2024-03-11
13F-HR/A2024-02-15
13F-HR2024-02-14
SC 13G/A2024-02-14
SC 13G/A2024-02-14
SC 13G/A2024-02-14
SC 13G/A2024-02-14
SC 13G/A2024-02-14

View Nantahala Capital Management's complete filings history.

Compare quarters

Export Nantahala Capital Management's holdings